Hematologic Malignancies: Clinical Trials

5 trials for Hematologic Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 21Completed 1

Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Denosumab, Zoledronic acid, Placebo to Denosumab - Cancer, Hematologic Malignancies
Phase 3CompletedAmgen17182012-05-172022-11-08
Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation
Red blood cell Transfusion - Hematologic Malignancies
Phase 3CompletedOttawa Hospital Research Institute3002011-03-012016-10-12
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
Posaconazole, ABLC - Invasive Fungal Infections, Hematologic Malignancies
Phase 3CompletedM.D. Anderson Cancer Center462008-06-012016-09-29
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia
Phase 2 / Phase 3CompletedGamida Cell -Teva Joint Venture Ltd.1012007-10-012015-07-10
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
Empirical Vancomycin, Prophylactic Vancomycin - Streptococcal Sepsis, Hematologic Malignancies
Phase 3CompletedMemorial Sloan Kettering Cancer Center1262003-11-012006-09-08

Narrower conditions

Hematologic Neoplasms (5)  ·  Blood Protein Disorders (1)  ·  Bone Diseases (1)  ·  Bone Marrow Diseases (1)  ·  Bone Neoplasms (1)  ·  Fractures, Bone (1)  ·  Hematologic Diseases (1)  ·  Hodgkin Disease (1)  ·  Invasive Fungal Infections (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)

Broader conditions

Hemic and Lymphatic Diseases (5)  ·  Neoplasms by Site (5)  ·  Hematologic Diseases (4)  ·  Neoplasms (4)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Bacterial Infections and Mycoses (1)  ·  Bone Marrow Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Chronic Disease (1)

Interventions

Amphotericin B (1)  ·  Denosumab (1)  ·  Erythrocyte Transfusion (1)  ·  Zoledronic Acid (1)  ·  posaconazole (1)

Sponsors

Amgen (1)  ·  Gamida Cell -Teva Joint Venture Ltd. (1)  ·  M.D. Anderson Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Ottawa Hospital Research Institute (1)

Countries

United States (4)  ·  Canada (2)  ·  Hungary (2)  ·  Italy (2)  ·  Spain (2)  ·  Australia (1)  ·  Austria (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hong Kong (1)  ·  Ireland (1)  ·  Israel (1)

Top investigators

Agha Mounzer, MD (1)  ·  Alberto Bosi, MD (1)  ·  Celia Grosskreutz, MD (1)  ·  Christelle Ferra, MD (1)  ·  Cristina Arbona, MD (1)  ·  Dr. Cristina Diaz de Heredia, MD (1)  ·  Dr. Mi Kwon, MD (1)  ·  Dr. Pere Barba, MD (1)  ·  Entezam Sahovic, MD (1)  ·  Guillermo Sanz, MD (1)  ·  Igor B. Resnick, MD, PhD (1)  ·  Issam Raad, MD/Professor (1)  ·  Jason Tay, MD FRCPC MSc (1)  ·  Jorge Sierra, MD (1)  ·  Ka Wah Chan, MD (1)

Results publications

PMID 22814329, PMID 29477778, PMID 32083994, PMID 34932836, PMID 41114449